The present application belongs to the field of pharmaceutical
chemistry and
antibacterial drug technology, and particularly relates to a C14 modified
pleuromutilin derivative, a preparation method thereof and application thereof in treating
gram-positive
bacteria, especially
gram-positive
drug-resistant bacterial infection. The C14 modified
pleuromutilin derivative provided by the present application has a structure shown in formula I or formula II. The present application introduces a heterocyclic
side chain (4-trifluoromethylphenylthiol or 1-(4,5-dihydrothiazole-2-yl)
azetidine-3-
thiol) at the C14 site of
pleuromutilin to synthesize the C14 modified pleuromutilin derivative, which significantly enhances the
antibacterial activity of the C14 modified pleuromutilin derivative on methicillin-resistant
Staphylococcus aureus (MRSA) and cfr
gram-positive bacterial strains, and has high
drug resistance barrier, low
cytotoxicity and hemolyticity. The C14 modified pleuromutilin derivative provided by the present application is suitable for treating multiple
drug-resistant bacterial infection in veterinary and
human medicine. Formula I, formula II.